194 related articles for article (PubMed ID: 1791526)
1. [The effect of chirality in clinical pharmacology].
Le Corre P; Sado P; Le Verge R
J Pharm Belg; 1991; 46(5):331-47. PubMed ID: 1791526
[TBL] [Abstract][Full Text] [Related]
2. Differential properties of enantiomers of commercially available racemates.
Gulati V
J Indian Med Assoc; 2007 Apr; 105(4):173-4, 176. PubMed ID: 17822184
[TBL] [Abstract][Full Text] [Related]
3. [Drug chirality].
Ricicová V; Rousová Z; Benes L
Ceska Slov Farm; 2002 Jan; 51(1):17-25. PubMed ID: 11910737
[TBL] [Abstract][Full Text] [Related]
4. Effect of chirality on pharmacokinetics and pharmacodynamics.
Crom WR
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S9-14. PubMed ID: 1530005
[TBL] [Abstract][Full Text] [Related]
5. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
Brocks DR
Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
Shah RR
Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
[TBL] [Abstract][Full Text] [Related]
7. [Chirality and drugs].
Testa B; Reist M; Carrupt PA
Ann Pharm Fr; 2000 Jul; 58(4):239-46. PubMed ID: 10915971
[TBL] [Abstract][Full Text] [Related]
8. [Chiral switch: pure enantiomers of drugs instead of racemic mixtures].
Valentová J; Hutt AJ
Ceska Slov Farm; 2004 Nov; 53(6):285-93. PubMed ID: 15630994
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional view of pharmacology.
Wainer IW
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S4-8. PubMed ID: 1530004
[TBL] [Abstract][Full Text] [Related]
10. Chirality: pharmacokinetics and pharmacodynamics in 3 dimensions.
Williams KM
Clin Exp Pharmacol Physiol; 1989 Jun; 16(6):465-70. PubMed ID: 2670353
[TBL] [Abstract][Full Text] [Related]
11. Chirality and its implications in transdermal drug development.
Reddy IK; Kommuru TR; Zaghloul AA; Khan MA
Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245
[TBL] [Abstract][Full Text] [Related]
12. Incoming guidelines on chirality. A challenge for pharmacokinetics in drug development.
Marzo A
Arzneimittelforschung; 1994 Jun; 44(6):791-3. PubMed ID: 8053982
[TBL] [Abstract][Full Text] [Related]
13. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs.
Reife RA
Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466
[TBL] [Abstract][Full Text] [Related]
14. Racemic mixtures: harmless or potentially toxic?
Ehrlich GE
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S15-8. PubMed ID: 1530003
[TBL] [Abstract][Full Text] [Related]
15. The FDA perspective on the development of stereoisomers.
De Camp WH
Chirality; 1989; 1(1):2-6. PubMed ID: 2642032
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic implications associated to the use of drugs as racemates or pure enantiomers].
Speisky H; Squella JA; Nuñez-Vergara LJ
Rev Med Chil; 1995 Jul; 123(7):884-91. PubMed ID: 8560121
[TBL] [Abstract][Full Text] [Related]
17. The future lies in chiral purity: a perspective.
Gurjar MK
J Indian Med Assoc; 2007 Apr; 105(4):177-8. PubMed ID: 17822185
[TBL] [Abstract][Full Text] [Related]
18. [Stereochemistry--an overlooked problem in medical treatment and research].
Mikkelsen EO
Ugeskr Laeger; 1990 Jul; 152(28):2029-32. PubMed ID: 2195737
[TBL] [Abstract][Full Text] [Related]
19. Drug chirality and its clinical significance.
Hutt AJ; Tan SC
Drugs; 1996; 52 Suppl 5():1-12. PubMed ID: 8922553
[TBL] [Abstract][Full Text] [Related]
20. Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites.
Coutts RT; Baker GB
Chirality; 1989; 1(2):99-120. PubMed ID: 2701850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
